Wings for Life

Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting KCC2, a key mediator of inhibition in the brain. The company utilizes a proprietary discovery engine centered on the neuron-specific K-Cl cotransporter (KCC2) to address various conditions, including epilepsy and pain, as well as other central nervous system pathologies. By harnessing breakthrough research from institutions such as Boston Children’s Hospital, Harvard, and Laval University, Axonis aims to enhance the lives of individuals affected by these disorders through improved modulation of neuronal inhibition.

ReNetX Bio, Inc. is a biotechnology company focused on developing therapeutics for injuries and damage to the central nervous system (CNS). Its primary product, Nogo Trap, is a decoy receptor that binds to growth inhibitors, facilitating the natural growth of nerve fibers and promoting processes such as axonal regeneration, axonal sprouting, and synaptic plasticity. The company's treatments address various CNS conditions, including spinal cord injury, stroke recovery, and glaucoma. Additionally, ReNetX Bio is involved in developing disease-modifying therapeutics aimed at conditions like Alzheimer's disease, utilizing small molecule oral compounds that inhibit the binding of β-amyloid oligomers in the brain. Founded in 2009 and based in New Haven, Connecticut, the company was previously known as Axerion Therapeutics, Inc. before rebranding in July 2017.